Highlights
- EPS (TTM)
- -$0.84
- Total Revenue (TTM)
- $51.13M
- Gross Profit (TTM)
- -$158.22M
- EBITDA (TTM)
- -$250.91M
- Year Range
- $1.11 - $2.70
- Target Price
- $8.87
- ROA (TTM)
- -38.16%
- ROE (TTM)
- -126.20%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Autolus Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Autolus Therapeutics plc (AUTL) has returned -30.65% so far this year and -10.97% over the past 12 months.
Autolus Therapeutics plc
- 1D
- 8.66%
- 1M
- -19.30%
- YTD
- -30.65%
- 6M
- -15.34%
- 1Y
- -10.97%
- 3Y*
- -9.14%
- 5Y*
- -25.24%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jun 22, 2018, AUTL's average daily return is -0.02%, while the average monthly return is -0.60%.
Historically, 38% of months were positive and 62% were negative. The best month was May 2023 with a return of +71.8%, while the worst month was Apr 2024 at -42.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 9 months.
On a daily basis, AUTL closed higher 47% of trading days. The best single day was May 12, 2021 with a return of +35.5%, while the worst single day was Dec 9, 2022 at -38.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -31.16% | 24.82% | -19.30% | -30.65% | |||||||||
| 2025 | -5.96% | -21.72% | -10.40% | -9.03% | 24.11% | 30.29% | 5.26% | -37.50% | 8.67% | -4.91% | -9.03% | 41.13% | -15.32% |
| 2024 | -6.52% | -0.33% | 6.33% | -42.32% | 13.86% | -16.95% | 34.77% | -16.20% | -7.63% | -7.16% | -1.48% | -29.22% | -63.51% |
| 2023 | 13.16% | -9.77% | -5.15% | -1.63% | 71.82% | -23.47% | 35.71% | -0.62% | -27.41% | 21.03% | 51.77% | 50.47% | 238.95% |
| 2022 | -23.12% | -6.27% | 11.50% | -25.18% | -12.18% | 3.28% | -1.41% | 18.28% | -35.15% | 33.18% | -7.37% | -28.03% | -63.39% |
| 2021 | -17.79% | -12.38% | -11.02% | 1.57% | 13.92% | 0.15% | -19.88% | 29.14% | -4.66% | -14.81% | 15.23% | -19.28% | -41.95% |
Benchmark Metrics
Autolus Therapeutics plc has an annualized alpha of -16.88%, beta of 1.06, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 25, 2018.
- This stock participated in 198.32% of S&P 500 Index downside but only 64.82% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.88%
- Beta
- 1.06
- R²
- 0.07
- Upside Capture
- 64.82%
- Downside Capture
- 198.32%
Return for Risk
Risk / Return Rank
AUTL ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and compare them to a chosen benchmark (S&P 500 Index).
| AUTL | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.13 | 0.90 | -1.03 |
Sortino ratioReturn per unit of downside risk | 0.41 | 1.39 | -0.98 |
Omega ratioGain probability vs. loss probability | 1.05 | 1.21 | -0.16 |
Calmar ratioReturn relative to maximum drawdown | -0.31 | 1.40 | -1.71 |
Martin ratioReturn relative to average drawdown | -0.48 | 6.61 | -7.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore AUTL risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Autolus Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Autolus Therapeutics plc was 97.63%, occurring on Apr 10, 2025. The portfolio has not yet recovered.
The current Autolus Therapeutics plc drawdown is 97.13%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.63% | Nov 12, 2018 | 1611 | Apr 10, 2025 | — | — | — |
| -27.36% | Sep 11, 2018 | 23 | Oct 11, 2018 | 20 | Nov 8, 2018 | 43 |
| -24.83% | Jun 27, 2018 | 12 | Jul 13, 2018 | 21 | Aug 13, 2018 | 33 |
| -5.65% | Aug 20, 2018 | 4 | Aug 23, 2018 | 10 | Sep 7, 2018 | 14 |
| -0.82% | Aug 14, 2018 | 1 | Aug 14, 2018 | 1 | Aug 15, 2018 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Autolus Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Autolus Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AUTL relative to other companies in the Biotechnology industry. Currently, AUTL has a P/S ratio of 7.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |